JPWO2020051356A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020051356A5
JPWO2020051356A5 JP2021512742A JP2021512742A JPWO2020051356A5 JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5 JP 2021512742 A JP2021512742 A JP 2021512742A JP 2021512742 A JP2021512742 A JP 2021512742A JP WO2020051356 A5 JPWO2020051356 A5 JP WO2020051356A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512742A
Other languages
Japanese (ja)
Other versions
JP2022501327A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049784 external-priority patent/WO2020051356A1/en
Publication of JP2022501327A publication Critical patent/JP2022501327A/en
Publication of JPWO2020051356A5 publication Critical patent/JPWO2020051356A5/ja
Pending legal-status Critical Current

Links

Claims (30)

式（Ｉ）の化合物：
Figure 2020051356000001
 またはその薬学的に許容される塩。
（ここで、
Ｒ１は、それぞれの存在において、独立して、Ｆ、Ｃｌ、Ｂｒ、またはＩ；
Ｒ２は、－Ｏ－（Ｃ３－５シクロアルキル）、－Ｏ－（Ｃ１－３ハロアルキル）、－Ｓ－（Ｃ１－３アルキル）、－Ｓ（Ｏ）（Ｃ１－３アルキル）、または－Ｓ（Ｏ２）（Ｃ１－３アルキル）；および
ｎは、０、１、２、３、または４である。） Compound of formula (I):
Figure 2020051356000001
 Or its pharmaceutically acceptable salt.
(here,
R 1 is independently F, Cl, Br, or I;
R2 is -O- (C 3-5 cycloalkyl), -O- (C 1-3 haloalkyl), -S- (C 1-3 alkyl), -S (O) (C 1-3 alkyl). , Or —S (O 2 ) (C 1-3 alkyl); and n is 0, 1, 2, 3, or 4. ) 前記式（Ｉ）の化合物が式（ＩＩ）の化合物
Figure 2020051356000002
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound of the formula (I) is a compound of the formula (II).
Figure 2020051356000002
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. Ｒ１がＦ、Ｃｌ、Ｂｒ、またはＩである、請求項１に記載の化合物。 The compound according to claim 1, wherein R 1 is F, Cl, Br, or I. Ｒ１がＦである、請求項１に記載の化合物。 The compound according to claim 1, wherein R 1 is F. Ｒ２が－Ｏ－（Ｃ３－５シクロアルキル）、－Ｏ－（Ｃ１－３モノハロアルキル）、－Ｏ－（Ｃ１－３ジハロアルキル）、－Ｏ－（Ｃ１－３トリハロアルキル）、－Ｓ－（Ｃ１－３アルキル）、－Ｓ（Ｏ）（Ｃ１－３アルキル）、または－Ｓ（Ｏ２）（Ｃ１－３アルキル）である、請求項１に記載の化合物。 R2 is -O- (C 3-5 cycloalkyl), -O- (C 1-3 monohaloalkyl), -O- (C 1-3 dihaloalkyl), -O- (C 1-3 trihaloalkyl) , -S- (C 1-3 alkyl), -S (O) (C 1-3 alkyl), or -S (O 2 ) (C 1-3 alkyl), claim 1. Ｒ２が、－Ｏ－ＣＦ３、－Ｏ－ＣＨ２－ＣＦ３、－Ｏ－シクロプロピル、－Ｓ－メチル、－Ｓ－エチル、－Ｓ（Ｏ）－メチル、－Ｓ（Ｏ）－エチル、－Ｓ（Ｏ２）－メチル、または－Ｓ（Ｏ２）－エチルである、請求項１に記載の化合物。 R 2 is -O-CF 3 , -O-CH 2 -CF 3 , -O-cyclopropyl, -S-methyl, -S-ethyl, -S (O) -methyl, -S (O) -ethyl. , -S (O 2 ) -Methyl, or -S (O 2 ) -Ethyl, according to claim 1. ｎが０である、請求項１に記載の化合物。 The compound according to claim 1, wherein n is 0. ｎが１である、請求項１に記載の化合物。 The compound according to claim 1, wherein n is 1. ｎが２である、請求項１に記載の化合物。 The compound according to claim 1, wherein n is 2. 前記化合物が、
Figure 2020051356000003
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000003
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000004
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000004
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000005
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000005
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000006
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000006
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000007
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000007
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000008
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000008
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000009
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000009
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000010
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000010
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000011
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000011
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 前記化合物が、
Figure 2020051356000012
 またはその薬学的に許容される塩である、請求項１に記載の化合物。 The compound is
Figure 2020051356000012
 The compound according to claim 1, which is a pharmaceutically acceptable salt thereof. 請求項１から１９のいずれか１項に記載の化合物を含む組成物。 A composition comprising the compound according to any one of claims 1 to 19. 請求項１から１９のいずれか１項に記載の化合物、またはその薬学的に許容される塩を含む医薬組成物。 A pharmaceutical composition comprising the compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof. 請求項１から１９のいずれか１項に記載の化合物、請求項２０に記載の組成物、または請求項２１に記載の医薬組成物であって、治療を必要とする対象に投与され、前記対象におけるウイルス感染の治療に用いられる化合物、組成物、または医薬組成物。 The compound according to any one of claims 1 to 19 , the composition according to claim 20, or the pharmaceutical composition according to claim 21, which is administered to a subject in need of treatment and is said to be the subject. Compounds, compositions, or pharmaceutical compositions used in the treatment of viral infections in. 前記ウイルス感染がＣ型肝炎ウイルス（ＨＣＶ）感染を含む、請求項２２に記載の化合物、組成物、または医薬組成物。 22. The compound, composition, or pharmaceutical composition of claim 22, wherein the viral infection comprises a hepatitis C virus (HCV) infection. 請求項１から１９のいずれか１項に記載の化合物、請求項２０に記載の組成物、または請求項２１に記載の医薬組成物であって、治療を必要とする対象に投与され、前記対象の癌の治療に用いられる化合物、組成物、または医薬組成物。 The compound according to any one of claims 1 to 19 , the composition according to claim 20, or the pharmaceutical composition according to claim 21, which is administered to a subject in need of treatment and is said to be the subject. A compound, composition, or pharmaceutical composition used in the treatment of cancer. 請求項１から１９のいずれか１項に記載の化合物、請求項２０に記載の組成物、または請求項２１に記載の医薬組成物であって、治療を必要とする対象に投与され、前記対象におけるヒト上皮成長因子受容体２（ＨＥＲ２）陽性癌の治療に用いられる化合物、組成物、または医薬組成物。 The compound according to any one of claims 1 to 19 , the composition according to claim 20, or the pharmaceutical composition according to claim 21, which is administered to a subject in need of treatment and said to the subject. A compound, composition, or pharmaceutical composition used in the treatment of human epidermal growth factor receptor 2 (HER2) -positive cancer in. 前記癌が食道、胃、結腸、直腸、膵臓、肺、***、子宮頸部、子宮体、卵巣、膀胱、頭頸部、子宮内膜、骨肉腫、前立腺、または神経芽細胞腫である、請求項２４または請求項２５に記載の化合物、組成物、または医薬組成物。 Claimed that the cancer is esophagus, stomach, colon, rectum, pancreas, lung, breast, cervix, uterine body, ovary, bladder, head and neck, endometrium, osteosarcoma, prostate, or neuroblastoma. 24 or the compound, composition, or pharmaceutical composition according to claim 25. 請求項１から１９のいずれか１項に記載の化合物、請求項２０に記載の組成物、または請求項２１に記載の医薬組成物であって、治療を必要とする対象に投与され、前記対象におけるアレルギー性疾患の治療に用いられる化合物、組成物、または医薬組成物。 The compound according to any one of claims 1 to 19 , the composition according to claim 20, or the pharmaceutical composition according to claim 21, which is administered to a subject in need of treatment and is said to be the subject. A compound, composition, or pharmaceutical composition used in the treatment of allergic diseases in. 請求項１から１９のいずれか１項に記載の化合物、請求項２０に記載の組成物、または請求項２１に記載の医薬組成物の、ウイルス感染症、癌、またはアレルギー性疾患の治療のための医薬品の製造における、使用。 For the treatment of viral infections, cancers, or allergic diseases of the compound according to any one of claims 1 to 19, the composition according to claim 20, or the pharmaceutical composition according to claim 21. Use in the manufacture of pharmaceutical products. 請求項１から１９のいずれか１項に記載の化合物を含む、治療を必要とする対象への投与に適した剤形。 A dosage form suitable for administration to a subject in need of treatment, comprising the compound according to any one of claims 1 to 19. 請求項１から１９のいずれか１項に記載の化合物およびその使用説明書を含むキット。 A kit comprising the compound according to any one of claims 1 to 19 and instructions for use thereof.
JP2021512742A 2018-09-07 2019-09-05 Imidazoquinoline compounds and their use Pending JP2022501327A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728556P 2018-09-07 2018-09-07
US62/728,556 2018-09-07
PCT/US2019/049784 WO2020051356A1 (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2022501327A JP2022501327A (en) 2022-01-06
JPWO2020051356A5 true JPWO2020051356A5 (en) 2022-07-04

Family

ID=69722888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512742A Pending JP2022501327A (en) 2018-09-07 2019-09-05 Imidazoquinoline compounds and their use

Country Status (9)

Country Link
US (1) US20210214354A1 (en)
EP (2) EP4306523A3 (en)
JP (1) JP2022501327A (en)
KR (1) KR20210074290A (en)
CN (1) CN113164460A (en)
AU (1) AU2019335366A1 (en)
CA (1) CA3111786A1 (en)
ES (1) ES2963112T3 (en)
WO (1) WO2020051356A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936377A1 (en) 2014-01-10 2015-07-16 Shanghai Birdie Biotech, Inc. Compounds and compositions for treating egfr expressing tumors
KR102462743B1 (en) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. Anti-pd-l1 combinations for treating tumors
CN112587672A (en) 2014-09-01 2021-04-02 博笛生物科技有限公司 anti-PD-L1 conjugates for the treatment of tumors
CN106943597A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti-EGFR for treating tumour is combined
CN115554406A (en) 2016-01-07 2023-01-03 博笛生物科技有限公司 anti-CD 20 combinations for the treatment of tumors
CN106943598A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
WO2018232725A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US689338A (en) * 1901-03-29 1901-12-17 Nat Faucet Company Tapping-bung.
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EA200600540A1 (en) * 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. INTRODUCTION OF TLR7 LIGANDS AND THEIR TREATMENTS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION
MX2007003078A (en) * 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Imidazoquinoline compounds.
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) * 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
MA39898B1 (en) * 2014-04-22 2020-08-31 Hoffmann La Roche 4-amino-imidazoquinoline compounds
CN105233291A (en) * 2014-07-09 2016-01-13 博笛生物科技有限公司 Combined therapy composition and combined therapy method for treating cancers
KR102462743B1 (en) * 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. Anti-pd-l1 combinations for treating tumors
CN105732635A (en) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 Toll-like receptor 7 agonist
CN106943598A (en) * 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti- HER2 for treating tumour is combined

Similar Documents

Publication Publication Date Title
JP2020507589A5 (en)
JP2020125349A5 (en)
JP2022031403A5 (en)
JP2021063088A5 (en)
JPWO2020051356A5 (en)
JP3987335B2 (en) L-enantiomer of cis-1- (2- (hydroxymethyl) -1,3-oxathiolan-5-yl) -5-fluorocytosine
JP2021100937A5 (en)
JP2019511483A5 (en)
JP2009507909A5 (en)
JP2020532532A5 (en)
JP2012529486A5 (en)
RU2007101236A (en) NEW HYDANTOINE DERIVATIVES FOR TREATMENT OF OBSTRUCTIVE RESPIRATORY DISEASES
JPH11512083A (en) 1,3-oxathiolane nucleoside analogs in the treatment of hepatitis C
JPWO2019212990A5 (en)
JP2005526064A5 (en)
JP2015536986A5 (en)
JP2021152063A5 (en)
JP2005508337A5 (en)
TWI609015B (en) 5-Hydroxyindan derivatives containing heterocyclic rings and uses thereof
JP2021102643A5 (en)
RU2008112181A (en) APPLICATION OF CONDENSED IMIDAZOLE DERIVATIVES FOR TREATMENT OF DISEASES MEDIATED BY CCR3 RECEPTOR
JP2022169780A5 (en)
TW201811323A (en) Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
JPWO2020037091A5 (en)
JP2006500372A5 (en)